Compare AbCellera Biologics Inc (ABCL) vs Global X Defense Tech ETF (SHLD) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

SHLD (Global X Defense Tech ETF) trades at $64.84, up 1.38% with a bullish technical signal supported by moving averages and ADX indicators. The defense sector benefits from global military spending growth, with recent UK defense overhaul and Pentagon AI investments driving positive sentiment. The ETF provides diversified exposure to defense technology companies amid accelerating global rearmament trends.

The outlook remains positive given structural defense spending increases, though competition from other defense ETFs and valuation concerns present risks. Technical indicators suggest potential resistance near $65-66 levels, while sector momentum supports continued investor interest in defense technology exposure.